9 METERS BIOPHARMA, INC.

2023 Q2 Form 10-Q Financial Statement

#000155198623000038 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.939M $37.24M
YoY Change -81.37% -3.27%
Cash & Equivalents $6.900M $37.24M
Short-Term Investments
Other Short-Term Assets $2.258M $1.846M
YoY Change 22.37% 23.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $9.197M $39.09M
YoY Change -76.47% -2.24%
LONG-TERM ASSETS
Property, Plant & Equipment $9.084K $17.31K
YoY Change -47.52% 14.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $8.980K $5.580K
YoY Change 60.93% 0.0%
Total Long-Term Assets $115.7K $176.5K
YoY Change -34.44% -21.17%
TOTAL ASSETS
Total Short-Term Assets $9.197M $39.09M
Total Long-Term Assets $115.7K $176.5K
Total Assets $9.313M $39.26M
YoY Change -76.28% -2.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.231M $1.912M
YoY Change 121.31% 39.48%
Accrued Expenses $5.758M $6.256M
YoY Change -7.96% 37.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $5.071M
YoY Change
Total Short-Term Liabilities $15.58M $8.224M
YoY Change 89.41% 37.37%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $34.77K $98.39K
YoY Change -64.66% -34.41%
Total Long-Term Liabilities $34.77K $98.39K
YoY Change -64.66% -34.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.58M $8.224M
Total Long-Term Liabilities $34.77K $98.39K
Total Liabilities $15.61M $8.323M
YoY Change 87.59% 35.5%
SHAREHOLDERS EQUITY
Retained Earnings -$226.5M -$180.2M
YoY Change 25.69% 31.06%
Common Stock $1.434K $25.82K
YoY Change -94.45% 19.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.299M $30.94M
YoY Change
Total Liabilities & Shareholders Equity $9.313M $39.26M
YoY Change -76.28% -2.35%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2022#DerivativeLiabilitiesCurrent
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001551986
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
CY2023Q1 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2022#DerivativeLiabilitiesCurrent
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-37797
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
9 METERS BIOPHARMA, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3948465
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
4509 Creedmoor Road
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Raleigh
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NC
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
27612
CY2023Q1 dei City Area Code
CityAreaCode
919
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
275-1933
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock $0.0001 Par Value
CY2023Q1 dei Trading Symbol
TradingSymbol
NMTR
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
112302 usd
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14459690 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6938991 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12646282 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1573725 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3358917 usd
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
684587 usd
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
17012650 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
9197303 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
33017849 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9084 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10413 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
97670 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8980 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7280 usd
CY2023Q1 us-gaap Assets
Assets
9313037 usd
CY2022Q4 us-gaap Assets
Assets
33147844 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4231034 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5053073 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5757675 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4379773 usd
CY2023Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
5071143 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
19616313 usd
CY2023Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
454000 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1585000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
63617 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
61746 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
15577469 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
30695905 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34773 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
51396 usd
CY2023Q1 us-gaap Liabilities
Liabilities
15612242 usd
CY2022Q4 us-gaap Liabilities
Liabilities
30747301 usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
550000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
550000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14336356 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14336356 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13036356 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13036356 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
1434 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1304 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
220174900 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
215006321 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-226475539 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-212607082 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-6299205 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2400543 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9313037 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
33147844 usd
CY2023Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
9799291 usd
CY2022Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8368478 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2988200 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2995771 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
12787491 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
11364249 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12787491 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11364249 usd
CY2023Q1 us-gaap Interest Income Other
InterestIncomeOther
164787 usd
CY2022Q1 us-gaap Interest Income Other
InterestIncomeOther
12814 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
752820 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
304 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-414291 usd
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-78642 usd
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1080966 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12510 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13868457 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11351739 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-13868457 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11351739 usd
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13591912 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13591912 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12911776 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12911776 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2400543 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
737000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
568291 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5000000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-13868457 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-6299205 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
41603313 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
690000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11351739 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
30941574 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-13868457 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11351739 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
737000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
690000 usd
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
578898 usd
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
CY2023Q1 us-gaap Depreciation
Depreciation
1329 usd
CY2022Q1 us-gaap Depreciation
Depreciation
1627 usd
CY2023Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
78642 usd
CY2022Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-414291 usd
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1783492 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1146448 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-822039 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-522659 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1347168 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
287992 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9749676 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9748331 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2842 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2842 usd
CY2023Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
16748001 usd
CY2022Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
0 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5000000 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
537677 usd
CY2022Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-12285678 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22035354 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9751173 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29658932 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46993285 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7623578 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37242112 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
173922 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q1 us-gaap Stock Issued1
StockIssued1
30614 usd
CY2022Q1 us-gaap Stock Issued1
StockIssued1
0 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6938991 usd
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37242112 usd
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
684587 usd
CY2022Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
0 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7623578 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37242112 usd
CY2020Q4 nmtr Sale Of Stock Shelf Registration Maximum Equity Offering Price
SaleOfStockShelfRegistrationMaximumEquityOfferingPrice
200000000 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Areas of the financial statements where estimates may have the most significant effect include fair value measurements, accrued expenses, share-based compensation, and management’s assessment of the Company’s ability to continue as a going concern. The Company considered the impact of the COVID-19 pandemic on its estimates and assumptions, and concluded there was not a material impact to its condensed consolidated financial statements as of and for the three months ended March 31, 2023. Changes in the facts or circumstances underlying these estimates could result in material changes and actual results could differ from these estimates.</span></div>
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1570885 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
427196 usd
CY2023Q1 nmtr Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
4086503 usd
CY2022Q4 nmtr Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
3833282 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
100287 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
119295 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5757675 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4379773 usd
CY2022Q3 nmtr Derivative Liability Term
DerivativeLiabilityTerm
P3Y
CY2022Q4 nmtr Derivative Liability Term
DerivativeLiabilityTerm
P2Y6M
CY2023Q1 nmtr Derivative Liability Term
DerivativeLiabilityTerm
P2Y6M
CY2023Q1 nmtr Derivative Liability Term
DerivativeLiabilityTerm
P0Y6M
CY2022Q3 us-gaap Share Price
SharePrice
4.87
CY2022Q4 us-gaap Share Price
SharePrice
1.26
CY2023Q1 us-gaap Share Price
SharePrice
2.42
CY2023Q1 us-gaap Share Price
SharePrice
1.39
CY2023Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
454000 usd
CY2023Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
454000 usd
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
1585000 usd
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
5380646 usd
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
100000 usd
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14800000 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2700000 shares
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14761958 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2662495 shares
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6900000 usd
CY2020Q2 nmtr Number Of Amended And Restated License Agreements
NumberOfAmendedAndRestatedLicenseAgreements
2 licenseagreement
CY2021Q3 nmtr Milestone Payment
MilestonePayment
500000 usd
CY2023Q1 nmtr Accrued Milestone Fees
AccruedMilestoneFees
0 usd
CY2022Q1 nmtr Accrued Milestone Fees
AccruedMilestoneFees
0 usd
CY2023Q1 nmtr Capital Stock Shares Authorized
CapitalStockSharesAuthorized
560000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
550000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14336356 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13036356 shares
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
18599583 shares
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
30893290 shares
CY2023Q1 nmtr Number Of Stock Option Plans
NumberOfStockOptionPlans
3 equity-basedincentiveplan
CY2023Q1 nmtr Share Based Compensation Arrangement By Share Based Payment Award Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedTerm
P10Y
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
737000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
690000 usd
CY2023Q1 nmtr Severance Provisions Annual Base Salary Period
SeveranceProvisionsAnnualBaseSalaryPeriod
P12M
CY2023Q1 nmtr Severance Provisions Continuation Of Health Insurance Benefits Period
SeveranceProvisionsContinuationOfHealthInsuranceBenefitsPeriod
P12M
CY2023Q1 nmtr Severance Provisions Termination Or Resignation Annual Base Salary Period
SeveranceProvisionsTerminationOrResignationAnnualBaseSalaryPeriod
P18M
CY2023Q1 us-gaap Severance Costs1
SeveranceCosts1
900000 usd
CY2022Q1 us-gaap Severance Costs1
SeveranceCosts1
0 usd
CY2023Q1 nmtr Deferred Compensation Liability Severance Accrual
DeferredCompensationLiabilitySeveranceAccrual
900000 usd
CY2022Q4 nmtr Deferred Compensation Liability Severance Accrual
DeferredCompensationLiabilitySeveranceAccrual
300000 usd
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2020Q3 nmtr Operating Lease Annual Rental Payments
OperatingLeaseAnnualRentalPayments
72000 usd
CY2020Q3 nmtr Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
6000 usd
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2020Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
233206 usd
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
233206 usd
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
18000 usd
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
18000 usd
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
100000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
54000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
54000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
108000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9610 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
98390 usd

Files In Submission

Name View Source Status
nmtr-20230331_cal.xml Edgar Link unprocessable
0001551986-23-000038-index-headers.html Edgar Link pending
0001551986-23-000038-index.html Edgar Link pending
0001551986-23-000038.txt Edgar Link pending
0001551986-23-000038-xbrl.zip Edgar Link pending
ex311q12023.htm Edgar Link pending
ex312q12023.htm Edgar Link pending
ex321q12023.htm Edgar Link pending
ex322q12023.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nmtr-20230331.htm Edgar Link pending
nmtr-20230331.xsd Edgar Link pending
nmtr-20230331_g1.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
nmtr-20230331_def.xml Edgar Link unprocessable
nmtr-20230331_lab.xml Edgar Link unprocessable
nmtr-20230331_pre.xml Edgar Link unprocessable
nmtr-20230331_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable